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SObjective: To evaluate 30-day and 90-day mortality after major pulmonary resection for lung cancer including
the relationship to hospital volume.
Methods:Major lung resections from 2007 to 2011 were identified in the National Cancer Data Base. Mortality
was compared according to annual volume and demographic and clinical covariates using univariate and
multivariable analyses, and included information on comorbidity. Statistical significance (P<.05) and 95%
confidence intervals were assessed.
Results: There were 124,418 major pulmonary resections identified in 1233 facilities. The 30-day mortality rate
was 2.8%. The 90-day mortality rate was 5.4%. Hospital volume was significantly associated with 30-day
mortality, with a mortality rate of 3.7% for volumes less than 10, and 1.7% for volumes of 90 or more. Other
variables significantly associated with 30-day mortality include older age, male sex, higher stage, pneumonec-
tomy, a previous primary cancer, and multiple comorbidities. Similar results were found for 90-day mortality
rates. In the multivariate analysis, hospital volume remained significant with adjusted odds ratios of 2.1
(95% confidence interval [CI], 1.7-2.6) for 30-day mortality and 1.3 (95% CI, 1.1-1.6) for conditional
90-day mortality for the hospitals with the lowest volume (<10) compared with those with the highest volume
(>90). Hospitals with a volume less than 30 had an adjusted odds ratio for 30-day mortality of 1.3 (95% CI,
1.2-1.5) compared with those with a volume greater than 30.
Conclusions:Mortality at 30 and 90 days and hospital volume should be monitored by institutions perform-
ing major pulmonary resection and benchmarked against hospitals performing at least 30 resections per year.
(J Thorac Cardiovasc Surg 2014;148:2269-78)See related commentary on page 2279.
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THospital volume has been repeatedly associated with the
outcome after specific complex surgical resections since
first reported by Luft and colleagues in 1979.1 The purpose
of this study was to determine the relationship between
hospital volume and outcome and to identify predictors of
improved outcome after major pulmonary resection for
cancer at 30 days, 90 days, and between 30 days and 90
days (conditional 90-day mortality) postoperatively using
the National Cancer Data Base (NCDB). We hypothesized
that overall 90-day mortality after a lung resection woulde Department of Surgery,a Abington Health, Abington, Pa; American College
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The Journal of Thoracic and Carbe significantly higher than 30-day operative mortality,
and that a volume/outcome relationship would persist.
Using the NCDB, the American College of Surgeons
(ACoS) Commission on Cancer (CoC) has the ability to
directly report individual annual volume and mortality
data to more than 1500 cancer programs, and to allow
programs to compare their data to all CoC-accredited
programs in the United States.METHODS
The NCDB is a joint project of the ACoS CoC and the American Cancer
Society and captures data from approximately 70% of all new cancers in
the United States treated at approximately 1500 facilities, including 82%
of all lung cancers.2 Institutional review board approval was not
required. Lung cancer cases diagnosed from 2007 to 2011 were retrieved
from the database. Selection criteria included age 18 years or older and
having had a surgical resection in the reporting facility. Lobectomies,
bilobectomies, and pneumonectomies were included, but not wedge
resections or other resections of less than 1 lobe.
There were 124,418 lung resections identified in 1233 facilities from
2007 to 2011 using the selection criteria. There were 2 hospitals with 40%
or more of cases missing 30-day mortality and 4 hospitals with 40% or
more of cases missing 90-day mortality. Excluding these hospitals resulted
in the exclusion of 17 cases for 30-day mortality and 129 cases for 90-day
mortality. An additional 3300 cases missing 30-day mortality regardless of
hospitalwere also excluded, resulting in 121,099 cases available for analysis
in 1231 hospitals. Overall, 95% of hospitals were missing 30-day mortality
for less than 10% of cases and 86% of hospitals were missing 30-daydiovascular Surgery c Volume 148, Number 5 2269
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CI ¼ confidence intervals
CoC ¼ Commission on Cancer
NCDB ¼ National Cancer Data Base
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Smortality for less than 5% of cases. After excluding 3389 deaths within
30 days and cases missing 90-day mortality, there were 114,905 cases avail-
able for analysis to assess conditional 90-day mortality (Figure 1).
Demographic and clinical characteristics of the analytical cases are
reported in Table 1. The mean age was 66.6 years; 42% of patients were
aged 70 years or older.
Ninety-three percent of resections were lobectomies or bilobectomies
and 7% were pneumonectomies. Nine percent of resections were
performed in hospitals with an annual surgical volume of less than 10 cases
a year, and 11%were performed in hospitals withmore than 90 resections a
year. The median annual volume for all resections was 33 cases per year.
Sixty-two percent of cases were stage 0, I, or occult, and 34% were stage
II or III. Twenty-four percent had 1 or more previous primary tumors (sites
unknown). Six percent of patients received neoadjuvant chemotherapy and
2% received neoadjuvant radiation.
Mortality within 30 and 90 days of the definitive surgery date was
determined, as well as mortality between 31 and 90 days from definitive
surgery (conditional 90-day mortality). Annual hospital volume was
determined by taking the average number of lung resections performed
from 2007 to 2011. Initially, 6 annual volume groups were examined:
less than 10, 10 to 19, 20 to 29, 30 to 39, 40 to 89, and more than 90
resections per year. Only currently accredited CoC hospitals were included,
and hospitals were required to have reported cancer cases each year
between 2007 and 2011. Hospitals with 40% or more of cases missing
30- or 90-day mortality were excluded (because of incomplete follow-up).
Demographic and clinical covariates were used in the univariate and
multivariable analyses. Mortality rates were similar for hospital volumes
between 10 and 29 and between 30 and 89, so 4 volume groups (0-9,
10-29, 30-89 and90) were used in the bivariate andmultivariate analyses.
NCDB comorbidity information is derived from up to 10 ICD-9-CM codes
recorded for each patient. These codes are used to categorize 28 Elixhauser
comorbidity groups,3 which have been found to be a better predictor of
outcomes than the Charlson Comorbidity Index.4,5 Patient income level
was not available but was determined from the zip code of residence and
the 2000 US Census Bureau median income for that zip code. Patient
residence was also categorized by census division.
Statistical Analyses
Overall 30- and 90-day mortality by annual hospital volume was
calculated. Because overall 90-day mortality includes deaths that occur
in the first 30 days, conditional 90-day mortality was calculated by
excluding deaths occurring within the first 30 days from definitive surgery.
Factors independently associated with mortality after 30 days can then be
evaluated using conditional 90-day mortality.
Thirty-day and conditional 90-day mortality were compared according
to annual hospital volume and demographic and clinical characteristics.
Statistical significance (P<.05) and 95% confidence intervals (CI) were
assessed using survey sampling methodology to account for clustering at
the hospital level. Multivariate analysis was conducted using a hierarchical
regression model that include a random effects model to account for patient
clustering within hospitals, using the GLIMMIX procedure in SAS (SAS
version 9.4, SAS Institute, Inc, Cary, NC). Variables in the model included2270 The Journal of Thoracic and Cardiovascular Surall those that were significantly associated with either 30-day or conditional
90-day mortality in the bivariate analyses.RESULTS
In the first 30 days after definitive surgery, 3389 deaths
occurred, resulting in a 30-day mortality rate of 2.8%
(95% CI, 2.7-2.9). A total of 6353 deaths occurred within
the first 90 days, resulting in an overall 90-day mortality
of 5.4% (95% CI, 5.2-5.6). After excluding the deaths in
the first 30 days, the conditional 90-day mortality was
2.6% (95% CI, 2.5-2.7) based on 2968 additional deaths
between 31 days and 90 days. Figure 2 displays the overall
30-day, conditional 90-day, and 90-day mortality by the 6
hospital volume groups. Figure 3 shows the overall
30-day, conditional 90-day, and 90-day mortality by 4
volume groups.
Thirty-day and conditional 90-day mortality and 95%
CIs by annual hospital volume and demographic/clinical
variables are displayed in Table 2. Hospital volume is signif-
icantly associated with 30-day mortality, with a mortality of
3.7% for volumes less than 10, and 1.7% for volumes of 90
or more. A small but significant decrease in 30-day mortal-
ity was found between 2007 and 2011. Other variables
significantly associated with 30-day mortality include older
age, male sex, lower median income, and living in the south-
ern US regions. Other factors significantly associated with a
higher 30-day mortality were higher stage, pneumonec-
tomy, a previous primary cancer, and neoadjuvant radiation.
Multiple comorbidities were significantly associated with
higher 30-day mortality; lower 30-day mortality was associ-
ated with 5 comorbidities (see Table 2).
Similar results were found for conditional 90-day mortal-
ity. Annual hospital volume was significantly associated
with conditional 90-day mortality although smaller differ-
ences were found compared with 30-day mortality. For
the lowest hospital volume group, the 90-day conditional
mortality rate was 2.9% compared with 2.2% in the highest
volume group. Significant associations were also found with
diagnosis year, age, sex, race, insurance status, and census
division. Clinical variables significantly associated with
conditional 90-day mortality include stage, surgery type,
having a previous cancer, and having had neoadjuvant radi-
ation and neoadjuvant chemotherapy. Comorbid conditions
significantly associated with conditional 90-day mortality
were similar to those for 30-day mortality.
Multivariate adjusted odds ratios are displayed in Table 3.
Annual hospital volume remained significantly associated
with 30-day mortality with an adjusted odds ratio of 2.1
(95% CI, 1.7-2.6), and with conditional 90-day mortality
with an adjusted odds ratio of 1.3 (95% CI, 1.1-1.6) for
the lowest compared with the highest hospital volume.
The adjusted odds ratio for 30-day mortality was 1.3
(95% CI, 1.2-1.5) for hospitals with annual volume less
than 30 compared with those with an annual volume greatergery c November 2014
FIGURE 1. Cohort selection examining mortality at 30 days and 90 days after major pulmonary resection for cancer from 2007 to 2011 in the National
Cancer Data Base.
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Sthan 30. Demographic variables remained significantly
associated with 30- and 90-day conditional mortality, with
the exception of race/ethnicity, which was not significantly
associated with 30-day mortality. Stage and surgery type
were significantly associated with 30-day and 90-day
conditional mortality.
Table 4 includes mortality rates for lobectomies and bilo-
bectomies versus pneumonectomies. Significant associations
with annual hospital volume for lobectomy/bilobectomyThe Journal of Thoracic and Carwere found for both 30-day and conditional 90-daymortality.
For pneumonectomies, hospital volumewas also significantly
associated with 30-day mortality but not 90-day conditional
mortality.
Evaluation of the potential effect of the 3317 cases
excluded for missing 30-day mortality information revealed
a similar distribution by annual hospital volume for these
excluded cases, with 2.5%, 2.9%, 2.5%, and 2.6% of those
with annual hospital volume of less than 10, 10 to 29, 30 todiovascular Surgery c Volume 148, Number 5 2271
TABLE 1. Demographic and clinical percentage distribution of lung
cancer resections, 2007 to 2011 (n ¼ 121,099)
Percentage
distribution Number of cases
Age
18-49 y 5.9 7140
50-59 y 17.5 21,207
60-69 y 34.6 41,877
70-79 32.9 39,919
80 9.0 10,956
Race
White 87.8 106,359
Black 8.6 10,438
Other 3.6 4302
Sex*
Male 50.7 61,367
Female 49.3 59,700
Insurance
Private, selfpay 33.8 40,918
None, Medicaid 5.0 6067
Medicare 56.8 68,780
Other government 3.2 3917
Unknown 1.2 1417
Median income quintilesy
<US$28,000 8.8 10,664
US$28,000-32,000 13.1 15,820
US$33,000-38,000 18.5 22,422
US$39,000-48,000 23.1 28,034
US$49,000 30.7 37,173
Unknown 5.8 6986
Census divisionz
New England 5.8 7075
Middle Atlantic 15.0 18,112
South Atlantic 22.5 27,301
East North Central 19.3 23,410
East South Central 8.5 10,329
West North Central 7.3 8904
West South Central 7.0 8532
Mountain 3.9 4691
Pacific 10.4 12,574
Out of United States 0.1 171
Average annual hospital volume, lung resections
0-9 9.0 10,860
10-19 18.4 22,233
20-29 17.5 21,176
30-39 11.7 14,227
40-89 32.1 38,928
90 11.3 13,675
Surgery type
Lobectomy/bilobectomy 93.4 113,150
Pneumonectomy 6.6 7949
Stage
0, I, occult 61.7 74,772
II 19.6 23,702
III 14.3 17,321
IV 2.6 3156
Unknown 1.8 2148
(Continued)
TABLE 1. Continued
Percentage
distribution Number of cases
Cancer sequence
Only or first primary 75.9 91,868
Second or higher primary 24.1 29,231
Neoadjuvant chemotherapy
No 94.4 114,128
Yes 5.8 6971
Neoadjuvant radiation
No 98.0 118,681
Yes 2.0 2418
*Excluding 32 cases, sex unknown or other. yBased on zip code level income from
2000 Census. zPatient residence. Census region states include New England (Maine,
Vermont, New Hampshire, Massachusetts, Connecticut, Rhode Island), Middle
Atlantic (New York, Pennsylvania, New Jersey), South Atlantic (West Virginia,
Maryland, Delaware, District of Columbia, Virginia, North Carolina, South Carolina,
Georgia, Florida), East North Central (Wisconsin, Illinois, Michigan, Indiana, Ohio);
East South Central (Kentucky, Tennessee, Mississippi, Alabama), West North Central
(North Dakota, South Dakota, New England, Kansas, Minnesota, Iowa, Missouri),
West South Central (Oklahoma, Arkansas, Louisiana, Texas), Mountain (Montana,
Idaho, Wyoming, Nevada, Utah, Colorado, Arizona, New Mexico), Pacific
(Washington, Oregon, California, Hawaii).
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S89, and 90 or more excluded. Missing 30-day mortality data
was much higher (7.9%) for the final year of the study
(2011) compared with the earlier 4 years (0.8%-2.3%).
The 30-day mortality observed for 2007 to 2010 (2011
data excluded) was 2.85% (95% CI, 2.74-2.95), which
was essentially the same as the 2.80% (95% CI,
2.70-2.89) for all 5 years of the study, including 2011.DISCUSSION
The current study has confirmed a relationship between
hospital volumes of major pulmonary resection for cancer
with 30-day mortality, and identified a statistically signifi-
cant difference in 90-day conditional mortality based on
annual hospital volume. In addition, a near doubling of
the (30-day) mortality rate by 90 days after surgery was
observed. The ongoing mortality between 31 and 90 days
postoperatively was seen across all volume groups, not
only in low volume groups, and warrants further study to
identify the causes of this delayed mortality.
Numerous studies dealing with the relationship of
hospital volume to operative mortality after resection of
lung cancer have been published,6-14 In 1992, Romano
and Mark6 reported the outcome of 12,439 adults who
underwent pulmonary resection through California hospital
discharge abstracts between 1983 and 1986. Mortality was
4.2% after lobectomy and 11.6% after pneumonectomy.
Multivariate regression models identified age greater than
60 years, male gender, extended resection, chronic lung or
heart disease, diabetes, and hospital volume as risk factors
for in-hospital mortality.
Bach and colleagues7 used the Surveillance, Epidemi-
ology, and End Results (SEER) Cancer Registry linked togery c November 2014
FIGURE 2. Thirty-day, conditional 90-day, and 90-day mortality rates, 95% confidence intervals, after major pulmonary resection by average annual
hospital volume group (6 groups).
FIGURE 3. Thirty-day, conditional 90-day, and 90-day mortality rates, 95% confidence intervals, after major pulmonary resection by average annual
hospital volume group (4 groups).
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TABLE 2. Unadjusted 30-day, conditional 90-day mortality rates by selected demographic, hospital, and clinical characteristics, and significant
comorbid conditions diagnosed between 2007 and 2011*
30-day mortality Conditional 90-day mortalityy
Mortality (%),
95% confidence intervals
Number of
deaths/number of cases
Mortality (%), 95%
confidence intervals
Number of
deaths/number of cases
All cases 2.8 (2.7-2.9) 3389/121,099 2.6 (2.5-2.7) 2968/114,905
Average annual volumez
0-9 3.7 (3.3-4.1) 404/10,860 2.9 (2.5-3.4) 303/10,278
10-29 3.1 (3.0-3.3) 1363/43,409 2.8 (2.6-3.0) 1146/41,035
30-89 2.6 (2.4-2.8) 1384/53,155 2.4 (2.3-2.6) 1238/50,615
90 1.7 (1.3-2.2) 238/13,675 2.2 (1.8-2.5) 281/12,977
Agez,x
18-49 y 1.2 (1.0-1.5) 88/7140 1.1 (0.8-1.3) 74/6857
50-59 y 1.5 (1.3-1.6) 313/21,207 1.5 (1.4-1.7) 311/20,330
60-69 y 2.2 (2.0-2.3) 911/41,877 2.1 (2.0-2.3) 853/40,009
70-79 y 3.7 (3.5-3.9) 1483/39,919 3.3 (3.1-3.5) 1239/37,570
80 y 5.4 (4.9-5.9) 594/10,956 4.8 (4.4-5.3) 491/10,139
Sexz,x,k
Male 3.7 (3.5-3.9) 2266/61,367 3.5 (3.3-3.7) 4279/59,987
Female 1.9 (1.7-2.0) 1122/59,700 1.7 (1.6-1.8) 2082/58,330
Unknown 2.7 (2.4-3.1) 192/6986 2.4 (2.0-2.8) 159/6610
Stagez,x
0, I, occult 2.3 (2.2-2.5) 1743/74,772 1.8 (1.7-1.9) 1307/71,315
II 3.4 (3.2-3.7) 810/23,702 3.2 (3.0-3.5) 724/22,280
III 3.8 (3.4-4.1) 653/17,321 4.3 (4.0-4.7) 706/16,283
IV 4.6 (3.8-5.3) 144/3156 7.5 (6.5-8.4) 220/2942
Unknown 1.8 (1.2-2.4) 39/2148 0.5 (0.2-0.9) 11/2085
Surgery typez,x
Lobectomy/bilobectomy 2.4 (2.3-2.5) 2726/113,150 2.3 (2.2-2.5) 2521/107,799
Pneumonectomy 8.3 (7.7-9.0) 663/7949 6.3 (5.7-6.9) 447/7106
Neoadjuvant chemotherapyx
Yes 2.8 (2.6-2.9) 210/6971 3.4 (3.0-3.9) 221/6479
No 3.0 (2.6-3.5) 3179/114,128 2.5 (2.4-2.7) 2747/108,426
Neoadjuvant radiationz,x
Yes 1.6 (1.1-2.2) 39/2418 3.8 (3.0-4.5) 87/2318
No 2.8 (2.7-3.0) 3350/118,681 2.6 (2.4-2.7) 2881/112,587
*Other variables significantly associated with 30-day and conditional 90-day mortality (not shown) include insurance, median income, census region, other primary cancers,
diagnosis years, and selected Elixhauser comorbidities including congestive heart failure, cardia arrhythmias, pulmonary circulation disorders, peripheral vascular disease,
hypertension, paralysis, other neurologic disorders, chronic pulmonary disease, renal failure, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anemia,
deficiency anemia, depression. Diagnosis year, vascular disease, complicated diabetes, and peptic ulcer disease were also significant in 30-day mortality only. Race and AIDS
were significant for conditional 90-day mortality. y90-day mortality excludes deaths within the first 30 days. zP .05, 30-day mortality. xP .05, 90-day mortality. k32 cases with
unknown sex excluded.
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Inpatient Sample (NIS) to examine 2118 patients more than
65 years of age undergoing resection for non–small cell
lung cancer between 1985 and 1996. They found a 3%
30-day mortality rate at the highest volume hospitals
compared with 6% at the lowest volume hospitals. They
also found improved 5-year survival by 11% (44% vs
33%) favoring the highest volume hospitals.
Birkmeyer and colleagues8 used Medicare claims data
and the NIS to examine 8 different major cancer resections
from 1994 to 1999, including 75,563 patients undergoing
lobectomy of the lung and 10,410 pneumonectomies. The
mortality rate for lobectomy varied from 4.2% to 6.4%
for the highest volume compared with the lowest volume2274 The Journal of Thoracic and Cardiovascular Surhospitals, respectively, with an adjusted odds ratio for
mortality of 0.70 (95% CI, 0.60-0.81) favoring the highest
volume group. An even larger overall difference in
mortality of 6.4% (10.6% vs 17%) was found for pneumo-
nectomy in the same extremes of volume groups.
Other studies have not found volume to be significantly
related to outcome.12,14-17 Kozower and Stukenborg9
examined 40,460 lung cancer resections performed at 436
hospitals using the 2007 NIS using 3 different methods.
The overall in-hospital mortality rate was 2.94%. Although
they found a statistically significant relationship for volume
when hospitals were categorized into quintiles, when
hospital volume was expressed as a continuous variable,
the association between volume and in-hospital mortalitygery c November 2014
TABLE 3. Adjusted odds ratios,* 95% confidence intervals for 30-day
and conditional 90-day mortality
Odds ratio, 95% confidence limits
30-day mortality
Conditional
90-day mortality
Average annual volume
90 1.0 (reference) 1.0 (reference)
30-89 1.4 (1.1-1.7) 1.0 (0.9-1.2)
10-29 1.7 (1.4-2.1) 1.2 (1.0-1.4)
0-9 2.1 (1.7-2.6) 1.3 (1.1-1.6)
Age group
18-49 y (reference) 1.0 (reference) 1.0 (reference)
50-59 y 1.2 (0.9-1.5) 1.4 (1.1-1.9)
60-69 y 1.9 (1.5-2.4) 2.0 (1.6-2.6)
70-79 y 3.3 (2.6-4.2) 3.2 (2.5-4.1)
80 y 5.2 (4.1-6.7) 5.1 (3.9-6.6)
Sex
Female 1.0 (reference) 1.0 (reference)
Male 1.6 (1.5-1.8) 1.8 (1.6-1.9)
Stage
0, I, occult 1.0 (reference) 1.0 (reference)
II 1.3 (1.2-1.4) 1.6 (1.5-1.8)
III 1.4 (1.3-1.6) 2.3 (2.0-2.5)
IV 1.9 (1.6-2.3) 4.5 (3.9-5.3)
Unknown 1.2 (0.8-1.6) 0.4 (0.2-0.8)
Surgery type
Lobectomy/bilobectomy 1.0 (reference) 1.5 (1.3-1.7)
Pneumonectomy 3.7 (3.4-4.1) 2.3 (2.1-2.6)
Neoadjuvant radiationy
No 1.0 (reference) 1.0 (reference)
Yes 0.5 (0.3-0.7) 1.0 (0.8-1.3)
Neoadjuvant chemotherapy
No 1.0 (reference) 1.0 (reference)
Yes 1.3 (1.1-1.5) 1.2 (1.1-1.4)
*All variables significant at P<.05 unless otherwise indicated. Other variables not
shown but included in the model: race, median income, insurance, census division,
previous cancers, diagnosis year, and the following Elixhauser comorbid conditions:
congestive heart failure, cardiac arrhythmias, pulmonary circulation disorders,
hypertension, paralysis, other neurologic disorders, chronic pulmonary disease, renal
failure, peptic ulcer disease, coagulopathy, weight loss, fluid and electrolyte
disorders, deficiency anemia, alcohol abuse, depression. yNot significant, conditional
90-day mortality.
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volume is not a predictor of mortality and should not be
used as a measure of quality. They stated that the most
important predictors of mortality after lung cancer resection
were patient age and comorbidities. Finlayson and
colleagues11 reported a significant relationship between
hospital volume and operative mortality for lobectomy but
not pneumonectomy. Freixinet and colleagues12 found no
effect of volume on outcomes in a Spanish multicenter
study of 2994 cases. Begg and colleagues13 did not find a
link between higher volume and lower mortality for
pneumonectomy using the SEER database.
Kozower and Stukenborg9 suggest that many previous
studies of volume and mortality are statistically flawed by
the use of arbitrary defined volume categories. They alsoThe Journal of Thoracic and Carpoint out the weakness of using administrative data. They
suggest that the very large numbers in large databases
make statistical significance easy to accomplish, but that
not all statistically significant results are clinically
significant. We believe that the 2-fold increase in adjusted
odds ratio for 30-day mortality seen in the present study
comparing the lowest with the highest volume groups is
both statistically significant and clinically significant, and
that the larger number of cases from a larger number of
institutions allowed us to identify this significant effect.
The overall mortality rate within 30 days of a major lung
resection in the NCDB from 2007 to 2011 was 2.8%, from
more than 1200 CoC-approved hospitals across the United
States. This is lower than the mortality rate from the
previous large studies6-9 and lower than reported from 2
European thoracic surgery units in 2007,15 but is higher
than the 2.2% mortality rate reported (in-hospital or within
30 days) in the Society of Thoracic Surgeons database
which examined 18,800 resections for lung cancer
(including wedge resections and segmentectomies) from
2002 to 2008 performed by a more select group likely to
be academic general thoracic surgeons at 111 hospitals.16
The 30-day mortality rate of 4.1% for the group more
than 70 years of age in the current study is lower than the
4.2%mortality rate reported at the highest volume hospitals
by Birkmeyer and colleagues8 just a decade before (in a
Medicare population). Historically, the Lung Cancer Study
Group reported 7.1% mortality for patients 70 years of age
and older in 1983.17 The low rate of pneumonectomy in this
study (7%), and the decline in the use of pneumonectomy
over the years, has clearly helped to lower the overall
surgical mortality after major pulmonary resection, but
the mortality rate for lobectomy has also significantly
declined over time as well, not just at the biggest and
highest volume hospitals but also when examined in all
CoC-accredited institutions across the United States
entering data in the NCDB.
The observation that the overall 90-day conditional
mortality rate (2.6%) in all patients was nearly as high as
the overall 30-day mortality rate (2.8%) after surgical
resection, leading to a 5.4% overall 90-day mortality after
major pulmonary resection, warrants further study. Powell
and colleagues18 have also recently reported that 3%
mortality at 30 days nearly doubled to 5.9% at 90 days in
an examination of 10,991 patients from a National Lung
Cancer Audit of English patients. The found that the
features of patients who died in the first 30 days were no
different from those who died between 31 and 90 days
postoperatively. They suggest that 90-day mortality risk,
not just 30-day mortality, should be considered preopera-
tively, and we would agree. Hu and colleagues14 reported
almost double mortality (3%-4% to 6.9%) in 11,787
patients who underwent resection comparing 30 days with
90 days in the linked SEER-Medicare Registry from 2006diovascular Surgery c Volume 148, Number 5 2275
TABLE 4. Unadjusted mortality rates, and risk-adjusted odds ratios by annual volume for lobectomy/bilobectomy only and pneumonectomy only,
2007 to 2011
30-day mortality* Conditional 90-day mortalityy
Lobectomy/bilobectomy
only (n ¼ 113,150;
2726 deaths)
Pneumonectomy
only (n ¼ 7949;
663 deaths)
Lobectomy/bilobectomy
only (n ¼ 107,799;
2521 deaths)
Pneumonectomy
only (n ¼ 7106;
447 deaths)
Overall mortality rate (%) 2.4 (2.3-2.5) 8.3 (7.7-9.0) 2.3 (2.2-2.4) 6.3 (5.7-6.9)
Annual volumez
<10 3.2 (2.9-3.6) 10.9 (8.4-13.5) 2.7 (2.3-3.1) 6.8 (4.8-8.8)
10-29 2.7 (2.6-2.9) 9.1 (8.0-10.3) 2.5 (2,4-2.7) 6.9 (5.8-7.9)
30-89 2.2 (2.0-2.4) 8.1 (7.1-9.0) 2.2 (2.0-2.4) 5.9 (5.0-6.8)
90 1.5 (1.1-1.9) 5.4 (4.0-6.7) 1.9 (1.5-2.3) 5.8 (4.3-7.3)
Annual volumez
<30 2.8 (2.7-3.0) 9.5 (8.5-10.5) 2.6 (2.4-2.7) 6.8 (5.9-7.8)
30 2.1 (1.9-2.2) 7.5 (6.6-8.3) 2.1 (2.0-2.3) 5.9 (5.1-6.6)
Adjusted odds ratiosx
Annual volumez
90 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
<10 2.0 (1.6-2.6) 2.2 (1.5-3.2) 1.3 (1.1-1.7) 1.2 (0.8-2.0)
10-29 1.6 (1.3-2.0) 1.7 (1.3-2.4) 1.2 (1.0-1.5) 1.2 (0.8-1.7)
30-89 1.3 (1.1-1.6) 1.5 (1.1-2.1) 1.1 (0.9-1.3) 1.1 (0.9-1.3)
Annual volumez
30 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
30 1.4 (1.2-1.5) 1.3 (1.1-1.5) 1.2 (1.1-1.3) 1.2 (1.0-1.5)
*P<.05, mortality rates by volume, adjusted hazard ratios by volume. yP>.05, mortality rates by volume and adjusted hazard ratios by volume. zAverage annual volume for
lobectomies/bilobectomies and pneumonectomies combined. xAdjusted for demographic and clinical variables.
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Sto 2010. Mortality after 30 days and after hospital discharge
up to 90 days postoperatively was studied using the
Rotterdam Cancer Registry; 3.6% 30-day mortality and
6.8% 90-day mortality was reported between 2006 and
2008.19
Some of the decrease in 30-day mortality seen in the
current study likely has resulted from the increased ability
to support critically ill patients postoperatively, delaying
some postoperative mortality beyond the traditional
30-day period often used to report operative mortality. A
broadened definition of operative mortality to include
30-day and in-hospital mortality during the initial
admission will still not capture patients discharged to
hospice care more than 30 days after surgery or who die
after discharge. Even the highest volume and highest
performing hospitals still had a combined 90-day mortality
rate of 3.9%, almost 1 death for every 25 patients resected.
The proportion of the conditional 90-day mortality that
occurred in the current study after discharge from the initial
hospitalization for pulmonary resection versus during a
prolonged initial hospitalization is not known.
Strengths of the current study of more than 120,000
patients treated at CoC-approved institutions include the
use of data from the NCDB entered by Certified Tumor
Registrars at each institution (not administrative data)
and the inclusion of only major pulmonary resections
(lobectomy, bilobectomy, and pneumonectomy). Although
the NCDB is a hospital-based and not a population-based2276 The Journal of Thoracic and Cardiovascular Surcancer registry, the ability to capture more than 80% of
all new lung cancer cases treated in the United States
each year, at both large and small institutions, academic
and community-based, allows a representative analysis
and reporting of care delivery across the United States to
all CoC-approved programs.
Missing data on 30-day mortality for 3300 cases,
although only 2.7% of all resections over this 5-year period,
are a weakness of this study. Amajor proportion of the cases
missing mortality data were treated in the final year of the
study (2011). The equal distribution of cases missing
data across the annual hospital volume groups, and the
equivalent mortality rate excluding the 2011 data
completely, suggest that the overall conclusions would not
be different. Another weakness relates to the Elixhauser
comorbidity groups taken from ICD-9-CM codes. It is not
always clear which ICD-9-CM codes were present
on admission versus those that might have developed
postoperatively or as a result of complications, such as
coagulopathy.
The doubling of the chance of death within 30 days after a
major pulmonary resection from the rate of 1.7% at the
highest volume hospitals to 3.7% at those hospitals per-
forming 9 or fewer major resections per year (risk-adjusted
odds ratio for mortality, 2.1; 95% CI, 1.7-2.6) represents a
variation in outcomes as well as an opportunity for improve-
ment in the care of these patients with potentially curable
lung cancer. A significant percentage of patients weregery c November 2014
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Streated at hospitals with an annual volume of less than 10
(9% of all resections) or an annual volume of less than 30
(45% of resections).
Given the relationship of volume to outcomes, and in the
interest of continued and continuous quality improvement,
hospitals should be aware of their annual volume for major
pulmonary resection and their institutional mortality
associated with those resections over time (at both 30
days and 90 days) compared with national data. Although
our methodology and analysis did not allow us to identify
an absolute break point or optimal minimum annual
volume, our data suggest the more the better and that
mortality continues to decline with increasing volume.
Benchmarking outcomes against those institutions perform-
ing more than 30 resections per year would attempt to
address much of the variation currently seen, and has
practical value. Those hospitals with low volume and/or
high mortality can then develop strategies to address the
differences in outcomes for their patients compared with
those treated at higher volume institutions with lower mor-
tality. Specific strategies to address low volume and/or high
mortality of major pulmonary resection are beyond the
scope of this report, but should be explored through future
efforts and investigation. To aid this process of continuous
quality improvement, the CoC now reports annual hospital
volume for major pulmonary resection, and 30-day mortal-
ity for those resections, to all CoC-approved programs
using NCDB data submitted by the hospitals on an annual
basis, as part of the Cancer Quality Improvement Program,
and starting in 2014 also plans to report 90-day mortality.References
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Dr Cameron D. Wright (Boston, Mass). Thank you, Dr Pezzi,
for a wonderful, very clear presentation. Using the National
Cancer Database to form a robust data set of 120,000 patients
who had a lung cancer resection, the authors have demonstrated
a modest, and I underline that word modest, volume/performance
relationship with an absolute mortality difference of 2% between
volumes less than 10 and greater than 90. The usual risk factors
for mortality were identified such as age. The authors picked a
somewhat arbitrary annual hospital volume of 30 without a
receiver operating characteristic curve analysis to define low
volume hospitals that they suggest should be carefully monitored
in terms of their results. Their volume/performance relationship
reporting is not new, and although this has been somewhat debated
in the literature, most reports do indeed suggest there is a modest
relationship, as this report does.
Of more interest to me is the substantial increase in mortality at
90 days, essentially doubling the 30-day mortality. This report
corroborates 2 very recent reports that also suggested doubling
of lung cancer mortality at 90 days, and in fact the mortality for
pneumonectomy at 90 days was a very sobering 14.6%. It begs
the question, are we misleading our patients when we counsel
them about their perioperative risk? We need to learn more about
what happens to our patients in this vulnerable period of time after
they are discharged to see if we can mitigate that risk. Obviously
this report cannot do that, but it certainly leads to an interesting
hypothesis and more work to be done. I have 2 questions.
First, why is there more volume/performance effect in the first
30 days versus the conditional 90 days? The odds ratio drops from
2 to a just slightly significant 1.3.
Dr Pezzi. Thank you, Dr Wright, for those comments and for
your first question, which is an excellent question. As far as the
reasons why we see a greater effect of volume on mortality during
the first 30 days than between 30 and 90 days, we honestly do
not know, but I wonder if this might suggest that some surgeon-
or institution-related factors are driving the 30-day mortality,diovascular Surgery c Volume 148, Number 5 2277
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factors, such as their tumors or comorbidities, are more respon-
sible for mortality between 30 and 90 days? We do still see an
effect on mortality between 30 and 90 days, but it is, as you
pointed out, significantly less. But this is just a hypothesis. I
certainly agree with you that we need to further study why these
patients are dying between 30 and 90 days, and hopefully that
will shed some light on what we can do to affect that mortality.
DrWright. And trending along that same line, where there is a
volume/performance relationship for pneumonectomy for the
30-day mortality, there is none for the conditional 90-day
mortality. Given the very large morbidity and mortality of
pneumonectomy, in which another 6% die in that 60-day window,
is this just a matter of small numbers? Why was that not
significant? What is your hypothesis there?
Dr Pezzi.Again, the overall magnitudewe saw across the board
seemed to decline between 30 and 90 days compared with the first
30 days, and perhaps we are dealing with small numbers, although
we did have 8000 pneumonectomies in this study, but perhaps it is
just small numbers. Again, I wonder if it could be patient-related
factors. I think as surgeons, we want to take responsibility for all
mortality of our patients, not just within 30 days, but even if a
patient dies 2 months later or 3 months later, I think we would
feel that somehow our operation might have contributed or had
something to do with that.
However, I think the longer we get out from the date of surgery,
it is possible that other factors beyond our control that are not
completely surgeon- or institution-related may be at play here,
and perhaps that is why we see a diminishing effect of volume
the further we get out from the date of surgery. This is just my
best guess to try to address your question.
Thank you very much for your comments and questions.
Dr Thomas K. Waddell (Toronto, Ontario). I enjoyed your
presentation. I want to follow up on Dr Wright’s question about
why the conditional mortality is not different in different size of
hospitals. Two questions to think about.
Are you able to describe any aspect of hospitals that have better
versus worse outcomes in that conditional mortality and are you
able to see postdischarge mortality as opposed to conditional
mortality based simply on the time points?
And the second question to think about, you presented
beautifully the evolution of 30-day mortality over time. Do you
have any data about the evolution of conditional mortality over
time? Is this also getting better or has it always been the same
magnitude of problem?
Dr Pezzi. To address your last question first, I think it is an
excellent question, and that is, we have traditionally defined
surgical mortality as 30 days or during the initial admission, and
so we do not have too much data on 90-day mortality over the
decades. And so I guess the question that comes to mind is: has
this mortality been there all along and we just did not notice it,
or is there something different now that we are essentially pushing
some of the mortality that used to occur in the first 30 days beyond
30 days? In talking to our surgical intensivists, they can keep sick2278 The Journal of Thoracic and Cardiovascular Surpatients alive longer, perhaps beyond 30 days, but maybe not
beyond 90 days. And so are we just pushing on some of that
mortality?
You talked about discharges. These are actually 30 and 90 days
and have nothing to do with hospitalization. We really did not look
at time of discharge or various hospitalizations. We are just
looking at crude survival at 30 and 90 days.
I think this is important, because at my own institution, if a
patient is doing poorly and they are not going to make it, and it
looks bad, and they have been on a ventilator for 4 weeks, a lot
of times they get sent to hospice and they are considered
discharged at that point and they are readmitted to hospice. And
so they would not be picked up as either a 30-day mortality or
an initial hospitalization mortality. They are considered
discharged. So I think that is an excellent point you bring up.
I hope I answered your question.
Dr Tomasz Grodzki (Szczecin, Poland). I have 1 short
question. Why did you decide that 90 cases per year is high
volume? European standards consider more than 200 as high
volume. It means that it is 2 cases per week. If you have 3 surgeons,
every single surgeon is doing less than 1 case per week. It is not a
high volume.
Dr Pezzi. Thank you. That is an excellent question. It was, as
Dr Wright pointed out and I would acknowledge, a weakness,
that it was somewhat arbitrary how we divided our volume groups.
I would point out that only 21 hospitals were in that high volume
group out of 1200. So to set the bar even higher would have led to
an even smaller number of hospitals.
Dr Mark J. Krasna (Neptune, NJ). Congratulations, Chris, to
you and the authors from the Commission on Cancer. I believe 1 of
the points also to take away from here, if I am not mistaken, is that
the Commission on Cancer data are currently reported back to the
hospitals, and it is not specified whether the surgeons performing
the operations were thoracic surgeons versus nonthoracic
surgeons. I do think it would be very interesting going forward
in a prospective fashion if you could get granular data to identify
not only the high volume from the low volume hospitals but also
identify hospitals where most of the surgery was done by thoracic
surgeons versus general surgeons.
I know in the past we have heard many papers about this, but
I do think using the NCDB data, we could maybe put in that
granularity and ask for that information going forward. I think it
is a very good start.
Dr Pezzi. Thank you very much. Yes, the NCDB currently is a
hospital-based registry, but they will be using National Provider
Identifier (NPI) numbers to report surgeon-specific data going
forward. It was not available in this data set, but in the future
that will be available using NPI numbers.
Dr Scott Swanson (Boston, Mass). Nice paper. One quick
question. You may have said it and I missed it. Why is 90 days
the max? Do we know what happens at 4 months, 6 months,
1 year? Does it flatten out and do you know that?
Dr Pezzi. That is an excellent question. We did not look at that
but I think we should.gery c November 2014
